Dec 9 (Reuters) - CVS Health (CVS) on Tuesday forecast 2026 profit above Wall Street estimates and this year's projected earnings, signalling steady progress in the health conglomerate's turnaround plan.
CVS stock rose 5% in early trading on Tuesday.
The company in October projected double-digit earnings growth for 2026 after raising its 2025 profit forecast for the third time.
"We are closing out 2025 with meaningful momentum across our businesses and we expect another year of strong earnings growth in 2026," said Chief Financial Officer Brian Newman on Tuesday.
The company forecast 2026 adjusted profit to be in the range of $7.00 to $7.20 per share, compared with analysts' average estimate of $7.16, according to data compiled by LSEG.
It, however, expects total revenue of at least $400 billion next year, below analysts' average estimate of $419.26 billion.
CVS also raised its 2025 adjusted profit forecast to $6.60 to $6.70 per share from $6.55 to $6.65 previously.
(Reporting by Sneha S K in Bengaluru; Editing by Shinjini Ganguli)
LATEST POSTS
- 1
Relentless rise in carbon pollution from fossil fuels slightly dampens climate-fighting hopes - 2I visited the largest collection of public telescopes in the US in Oregon's high desert, and the dark skies blew me away
- 3Vote in favor of your Number one natural product
- 4Members of Kenya-led security mission in Haiti were involved in rapes, U.N. says
- 5New movies to watch this weekend: See 'The Running Man' in theaters, rent 'One Battle After Another,' stream 'Nobody 2' on Peacock
- Why do people get headaches and migraines? A child neurologist explains the science of head pain and how to treat it
- Step by step instructions to Get a good deal on Your Rooftop Substitution Venture
- The most effective method to Go with Informed Choices on Vehicle Leases
- Kiefer Sutherland arrested after allegedly assaulting a ride-share driver in L.A.
- Figure out How to Explore Land Close to 5G Pinnacles
- Pentagon advances Golden Dome missile defense with new Space Force contracts
- Health Rounds: Regeneron drug wipes out residual multiple myeloma cells in small trial
- Meet the astronauts about to make history on flight around the moon
- Divorce filings, feuds and legal trouble: The 'Mormon Wives' drama keeps piling up
